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ABSTRACT. Ligands for retinoid X receptors (RXRs), “rexinoids”, are attracting interest as candidates 
for therapy of type 2 diabetes, Alzheimer’s and Parkinson’s diseases. However, current screening 
methods for rexinoids are slow and require special apparatus or facilities. Here, we created 7-hydroxy-2-
oxo-6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-2H-chromene-3-carboxylic acid (10, 
CU-6PMN) as a new fluorescent RXR agonist and developed a screening system of rexinoids using 10. 
Compound 10 was designed based on the fact that umbelliferone emits strong fluorescence in a 
hydrophilic environment, but the fluorescence intensity decreases in hydrophobic environments such as 
the interior of proteins. The developed assay using 10 enabled screening of rexinoids to be performed 
easily within a few hours by monitoring changes of fluorescence intensity with widely available 
fluorescence microplate readers, without the need for processes such as filtration. 
 
INTRODUCTION 
There are 48 types of human nuclear receptors that regulate gene expression in response to binding of 
small-molecular ligands1,2. Among them, retinoid X receptors (RXRs) often act as heterodimers with a 
variety of other receptors, and ligands targeting RXR (known as rexinoids3) can control the activities of 
these RXR heterodimers. Since RXRs are activated by low concentrations of 9-cis retinoic acid (1)4 
(Figure 1), 1 had been considered as an endogenous ligand, though it has not been detected in blood5. 
More recently, 9-cis-13,14-dihydroretinoic acid (2) (Figure 1) has been suggested to be an endogenous 
ligand of RXR6. Many synthetic rexinoids have also been reported. Among them, bexarotene (3) (Figure 
1) is an activator (agonist) of RXR and is used clinically to treat cutaneous T cell lymphoma (CTCL)7. It 
may also be effective against diabetes3, Alzheimer's disease8,9, and Parkinson's disease10,11. The basis of 
these activities is thought to be activation of RXR heterodimers with nuclear receptors such as 
peroxisome proliferator-responsive receptors (PPARs), liver X receptor (LXR), and nuclear receptor 
related 1 protein (Nurr1), which are involved in the regulation of sugar and lipid metabolism, 
inflammation and other processes. The ability of RXR agonists to regulate these RXR heterodimers via 
their action on RXR alone is known as the permissive mechanism of activation12. On the other hand, 
polyunsaturated fatty acids such as docosahexaenoic acid (DHA, 4) (Figure 1) are natural rexinoids13,14. 
They are reported to improve memory and metabolic syndrome15, and foods containing them are used as 
functional foods. Other compounds, including various environmental pollutants, can have adverse 
effects on nuclear receptors, for example serving as endocrine disruptors16. Therefore, there is a great 
demand for a simple, low-cost assay system that can identify compounds with RXR ligand activity, not 
only for drug discovery, but also for studies on functional foods and endocrine disruptors. 
 
 
Figure 1. Chemical structures of 1–11 and molecular design strategies used here. 
 
Existing rexinoid search technologies are summarized below and in Table 1.  
1) Reporter gene assay4: This assay evaluates not only transcriptional activation, but also cell 
permeability of test compounds, because it employs living cells transfected with reporter plasmid 
encoding a reporter gene such as luciferase under an RXR response element. However, it requires a long 
time (3–4 days).  
2) Time-resolved fluorescence resonance energy transfer (TR-FRET)17: This assay reveals recruitment 
of a co-activator peptide by test compounds within a short period. However, a special plate reader is 
required. 
3) Binding assay using a radioisotope-labeled ligand18: This assay can assess the binding affinity of 
test compounds for RXR with high sensitivity, using a small amount of RXR peptide. However, this 
method requires a radioactive tracer (such as [3H]1), as well as bound/free (B/F) separation. The 
procedure is complicated and involves radioactivity-related safety issues. 
4) Fluorescence quenching method (FQM)19,20:  This method is based on the quenching of 
autofluorescence derived from tryptophan in the ligand-binding site (LBD) of RXR. However, the 
autofluorescence of tryptophan is weak and the fluorescence wavelengths (Ex/Em 280/337 nm) are 
outside the range of usual plate readers. 
 
Table 1. Existing Rexinoid Search Technologies 
 Measurement Principle Advantages Disadvantages 
Reporter gene 
assay4 
Evaluation of transcriptional 
activation ability of test 
compounds using cells 
overexpressing RXRs 
Transcription 
activation by test 
compounds can be 
measured. 








FRET phenomenon between a 
terbium-labeled RXR and a 
coactivator labeled with 
fluorescein 
Activation of RXR 
by test compounds 
can be measured in 
a short period. 
A special plate 







Based on competition of test 
compounds and radio-labeled 
compound for binding to RXRs 
Highly sensitive. 
Small amount of 










Binding of test compound 
quenches the autofluorescence of 
Measurement can 
be done just by 
Usual plate 
readers are not 
method 
(FQM)19,20  
tryptophan in RXRs. mixing RXR-LBD 
and test compound. 
suitable (Ex/Em 
280/337 nm are 
outside usual 





Other reported RXR ligand screening methods include cell-based RXR assays such as a yeast reporter 
assay21; magnetic microbead affinity selection screening (MagMASS) to find RXR ligands in complex 
mixtures22,23 and virtual screening approaches for RXR ligands24. However, cell-based RXR assays 
require a long time (3–4 days). MagMASS requires HPLC-MS apparatus. As for virtual screening, it is 
always necessary to experimentally confirm the binding affinity of candidate RXR ligands. 
Thus, to overcome the disadvantages of existing methods, we set out to design a fluorescent rexinoid 
that would be suitable for use in a simple, highly sensitive RXR binding assay. We previously reported 
the fluorescent RXR agonist 5 (Figure 1), which has a fluorescent carbostyril structure 6 in place of the 
1,1,4,4-tetramethyltetralin structure of 3. Compound 5 has been used in a fluorescence polarization-
based assay targeting RXRs.25 However, the RXR agonist activity of 5 was much weaker than that of 3 
(the EC50 values were 1 µM and 20 nM, respectively), and its relatively poor binding ability to RXRs 
was a significant drawback. Therefore, in this study, we aimed to create a new fluorescent RXR agonist 
that would be suitable for highly sensitive RXR ligand screening using a standard fluorescence plate 
reader. 
RESULTS AND DISCUSSION 
Pohl et al. reported fluorescent retinoids targeting cellular retinoid binding protein II (CRABPII)26,27. 
Compared to CRBPII, less space is available in the ligand-binding site of RXR25, and therefore we 
considered that the acidic domain of RXR agonists would have to be converted to a fluorophore. 
Umbelliferone (7) is a fluorophore that can be detected with a widely available fluorescent filter set 
(Ex 360 nm/ Em 465 nm)28. Its derivative 8 with a carboxy group at the 3-position has a 7-hydroxyl 
group, which exists in OH form in a hydrophobic environment, but as the anion (O-) in an aqueous 
environment, resulting in an increase of fluorescence intensity29. Thus, if the receptor-bound compound 
is displaced by a competively binding RXR ligand, an increase of the fluorescence intensity will be 
observed. With this in mind, we designed and synthesized 10 (Design 1), which has an umbelliferone 
skeleton, and its regioisomer 11 (Design 2) based on the chemical structure of the RXR agonist CD3254 
(9).30 Since 9 has a cinnamic acid structure, we anticipated that this structure could be developed 





aReagents and conditions: a) conc. HCl, b) 2-bromotoluene, AlCl3, DCM, 78% for 2 steps. c) 1) n-
BuLi, B(Oi-Pr)3, THF. 2) 2 M HCl, 73%. d) Br2, AcOH, 28%. e) MOMCl, DIPEA, DMF, 92%. f) 4, 
Pd(PPh3)4, 2 M Na2CO3, EtOH, toluene, 86%. g) 4 M HCl/EtOAc, 88%. h) Meldrum's acid, piperidine, 
EtOH, 55%. 
 
Scheme 2. a 
 
aReagents and conditions: a) MOMCl, NaH, DMF, q.y. b) 1) n-BuLi, Et2O, 2) B(OMe)3, 49%. c) 14, 
Pd(PPh3)4, K3PO4, DME, H2O, 78%. d) 4 M HCl/EtOAc, 54%. e) POCl3, DMF, 39%. f) Meldrum's acid, 
piperidine, EtOH, 46%. 
 
In reporter assay, 10 showed potent RXR activation (EC50 = 22 nM toward human RXRα), like 3 
(Figure 2A). In binding assay using human RXRα ligand-binding domain (hRXRα-LBD), both 
compounds showed concentration-dependent competition with [3H]1 (Figure 2B). The IC50 values were 
calculated from the binding data, and the inhibition constant (Ki) of each compound was determined 
using the Cheng-Prusoff equation.31  The Ki values for 3 and 10 were 150 nM and 230 nM, respectively. 
However, the behavior of 10 was different from that of 3, in that [3H]1 was not completely displaced 
from the receptor by 10. In addition, at the lower concentration of 10, the % of bound [3H]1 was 
increased compared to that in the absence of 10 as a competitor.  
 
 
Figure 2. Transactivation of human RXRα (hRXRα) by 3, 10 and 11 and binding to human RXRα 
ligand-binding domain (hRXRα-LBD) of 3 and 10 in the presence of [3H]1. (A) Dose-dependent 
agonistic activity curves of 3 (open circles), 10 (closed circles) and 11 (closed diamonds) toward 
hRXRα in COS-1 cells. The data are shown as relative transactivation activity with respect to 1 µM 3, 
taken as 1. Data are mean ± SD (n = 3). (B) Dose-dependent binding of [3H]1 with hRXRα-LBD in the 
presence of 3 (open circles) or 10 (closed circles). The data are shown as % of the value of [3H]1 in the 
absence of any competitive sample. [3H]1 and hRXRα-LBD were used at concentrations of 10 nM and 
50 nM, respectively. Data are mean ± SD (n = 3). 
 
To reveal the reason for these incongruities, we conducted X-ray structure analysis. The crystal 
structure of the hRXRα-LBD/10 (green) complex was determined at 2.65 Å resolution (Figure 3, Table 
S1) (PDB code 6JNO). The structure turned out to be tetrameric and the coupling ratio of 10 to RXRα-
LBD was predicted as 4 to 2 based on the electron density map of hRXRα-LBD/10 complex. In addition, 
this confirmed that 10 binds at the dimer-dimer interface, in contrast to 1 (PDB ID: 3OAP),32 and this 
may be the reason why [3H]1 was not completely displaced from the receptor by 10. Though ligand-
binding at the dimer-dimer interface has already been reported for RXR antagonists rhein (PDB ID: 
3R2A),33 K8003 (PDB ID: 5TBP),34 and K8008 (PDB ID: 4N8R)35 (Figure S1), this is the first example 
of an RXR agonist binding at this location. Since 10 has RXR agonist activity and showed 
concentration-dependent competition with [3H]1, it seems likely that 10 also binds to the ligand-binding 
pocket (LBP) of the hRXRα-LBD, like 3, as well as to the dimer-dimer interface. However, it is still not 
clear why a low concentration of 10 promoted the binding of [3H]1. One possibility might be that 
binding of 10 to the interface induces some structural change at the LBP.  
 
Figure 3. Structure of the complex of 10 with the hRXRα-LBD. (A) Comparison of ligand-binding 
modes in hRXRα-LBD. The hRXRα-LBD in the complexes with 10 (PDB ID: 6JNO) and 1 (PDB ID: 
3OAP)32 is shown in green and orange, respectively. The binding site of 10 to the hRXRα-LBD is 
located at the interface between the two domains of the hRXRα-LBD. (B) The 2Fo-Fc electron density 
map (blue color) was contoured at 0.50 σ. (C) Comparison of ligand-binding modes in hRXRα-LBD. 
The binding modes of rhein (PDB ID: 3R2A),33 K8003 (PDB ID: 5TBP),34 K8008 (PDB ID: 4N8R),35 
and 10 are shown in cyan, magenta, yellow and green, respectively. 
 
The fluorescence properties of 10 were examined. The maximum absorbance of 10 in 0.1 N aqueous 
solution of sodium hydroxide was 396 nm, the maximum fluorescence wavelength was 453 nm, and the 
fluorescence quantum yield was 0.47 (Table 2, Figure S2). In addition, when the fluorescence intensity 
was measured with fixed excitation and fluorescence wavelengths (Ex 360 nm/ Em 465 nm) in several 
solvents with different polarity, the fluorescence intensity of 10 decreased significantly as the solvent 
polarity decreased (Figure 4B). This suggests that a decrease in the fluorescence intensity of 10 can be 
expected upon binding to RXR, due to the more hydrophobic environment, as anticipated. Thus, the 
binding ability of 10 to RXR was determined based on the change in the fluorescence intensity of 10 
upon binding to the hRXRα-LBD (Figure 4C). The experimental protocol is described in the supporting 
information. After sample mixing at room temperature, the measured intensity became stable at 2 hours, 
so all fluorescent measurements were made under these conditions. The fluorescence intensity of 10 
decreased in a sigmoid manner depending on the concentration of hRXRα-LBD (Figure 4C), and a Hill 
coefficient (n) of 1.9 and dissociation constant (Kd) of 233 nM were obtained (Figure 4D). A Hill 
coefficient of >1 indicates positive cooperativity, i.e., binding of the first ligand facilitates binding of a 
second ligand at another site on the dimeric receptor complex. Imai et al. reported similar results for a 
fluorescent ligand targeting the homodimeric estrogen receptor.36 The fact that the Hill coefficient is 
greater than 1 implies that binding of 10 to RXRs induces positive cooperativity, i.e., binding of 10 to 
RXRs induces further binding of 10. 
 
Table 2. Absorption and Fluorescence Data of 10 in 0.1 N NaOH and MeOH, respectively 
Solvent 
ε λAbs λEm 
Φ [L/(mol·cm)] [nm] 
0.1 N NaOH 1.78 × 104 396 453 0.468 ± 0.003 
MeOH 6.71 × 103 352 453 0.095 ± 0.02 
n = 3, mean ± SD 
 
 
Figure 4. Characterization of 10. Relative absorbance and fluorescence spectra of 10 in 0.1 N NaOH. 
(A) Fluorescence spectra were obtained at Ex/Em = 396 nm/453 nm. (B) Relative fluorescent intensity 
data of 100 nM 10 in various solvents containing 1% DMSO (Ex/Em = 360 nm/465 nm). (C and D) 
Specific binding curve (C) and Hill plot (D) of 10 with hRXRα-LBD. “Rf” is the concentration of free 
receptor. Final concentration of 10 was 300 nM in assay buffer containing 10 mM Hepes, 150 mM NaCl, 
2 mM MgCl2, 5 mM DTT (pH7.9). DMSO final concentration was 1%. Ex/Em=360 nm/465 nm. Data 
are mean ± SD (n = 4). 
 
Next, the affinity of test compounds for RXR was determined using 10 and hRXRα-LBD in a 384-
well plate. To each well (4 wells per sample), 10 µL of hRXRα-LBD at 1 µM (final concentration 0.5 
µM), 5 μL of the sample at 4 times higher concentration than the final concentration, and 5 µL of 400 
nM 10 (final concentration 100 nM) were added. The mixture was incubated for 2 hours at room 
temperature and the fluorescence intensity was measured. This incubation time was chosen based on 
evaluation of the Z’-factor at incubation times of 0.5, 1, 2, 3 hours for 1, 10 and hRXRα-LBD (Figure 
S3). The IC50 was calculated from the fluorescence intensity data, and the Ki of each compound was 
determined using the Cheng-Prusoff equation.31 The experimental protocols and data analysis methods 
are described in the supporting information. The Ki values are shown in Table S2. Figure 5A compares 
the results of radioisotope (RI) experiments using [3H]1 and the assay using 10 to measure the binding 
ability of known rexinoids to hRXRα-LBD (Figures S4 and S5). Because of limited availability, we 
used commercially available hRXRα-LBD for the RI experiment, and our prepared protein for the 
binding assay using compound 10. The correlation coefficient between Ki values determined by the two 
methods was about 0.7, despite the difference in hRXRα-LBD preparation used. However, rexinoids 
that gave small Ki values in RI, such as NEt-3IB (Figure S4), gave Ki values one order of magnitude 
higher as determined in the assay using 10. The reason for this is not clear, but might be related to 
failure of 10 to completely displace [3H]1, observed in the RI experiments. Because polyunsaturated 
fatty acids are known to function as rexinoids13,14, their binding ability to RXR was also examined using 
the developed method (Figure 5B and Table S3). A higher concentration of DHA (4) was required for 
binding to RXR, compared to bexarotene (3), while no binding of palmitic acid was observed, in 
accordance with previous reports.37 Interestingly, our system revealed the binding affinity of 
eicosapentaenoic acid (EPA), which has not reported before. We also evaluated some readily available 
RXR antagonists using this method and confirmed the order of binding affinity (Figures S6 and S7, and 
Table S3). Thus, our system provides simple and sensitive methodology with readily available 
equipment for the initial screening of RXR ligands, though the agonistic or antagonistic activity of hits 
would need to be separately examined. 
 
 
Figure 5. Competitive binding assay using 10. (A) Correlation of hRXR-LBD binding affinity values 
obtained with 10 and [3H]1. The Ki values obtained with 10 and those obtained with [3H]1 are plotted 
on the X and Y axes, respectively. (B) Relative fluorescence intensity curves of test compounds in the 
assay using 10. These data were calculated by subtraction of the fluorescence values for the hRXRα-
LBD with the test compound in the absence of 10 from those in the presence of 10. The y-axis is shown 
as the relative value to 10 µM 3, taken as 1 (positive control). This assay was performed in a 384-well 
plate (4 wells/sample). Final concentrations of 10 and hRXRα-LBD were 100 nM and 500 nM, 
respectively. Each compound except for 3 was added at 0.20, 0.39, 0.78, 1.56, 3.13, 6.25, 12.5, 25, 50 
and 100 µM (final concentration). Assay buffer contained 10 mM Hepes, 150 mM NaCl, 2 mM MgCl2, 
5 mM DTT (pH 7.9). DMSO final concentration was 1%. Ex 360 nm/Em 465 nm. Data are mean ± SD 
(n = 4). 
 
CONCLUSIONS 
In this study, we designed and synthesized an umbelliferone derivative 10 as a new fluorescent 
rexinoid, and applied it to develop a fluorescence-based RXR-binding assay system for screening 
rexinoids. This assay system is simple, sensitive, and can be performed in a few hours with widely 
available fluorescence microplate readers, without the need for processes such as filtration. Though 
there remains an issue concerning the correlation of this assay system with RI experiments, this assay is 
expected to be useful for simple, rapid, low-cost screening studies. Hit compounds can then be followed 
up by assessing transcriptional activity by means of reporter gene assay. We believe it will be useful not 
only for identifying RXR binders in drug discovery studies, but also for studies of functional foods and 
endocrine disruptors, though it should be noted that fluorescence-based assays often suffer from 




General. All solvents and chemicals were used as purchased without further purification. The progress 
of all reactions was monitored by thin layer chromatography (TLC) on 0.2 mm thick TLC plates (Merck, 
glass-backed, silica gel 60 F245), and spots were detected under UV light. Silica gel 60 (Kanto 
Chemical, particle size 0.04–0.05 mm) was used for purification by flash column chromatography. 1H 
NMR and 13C NMR spectra were measured on a Varian Mercury-300 (1H 300 MHz, 13C 75 MHz) 
spectrometer or a Varian VXR-400 (1H 400 MHz) spectrometer at room temperature. Deuterated 
chloroform and dimethyl sulfoxide (CDCl3 and DMSO-d6) were used as solvents in all routine NMR 
measurements. Chemical shifts are reported in ppm relative to the respective deuterated solvent peak, 
CHCl3 (δ 7.26 ppm), DMSO-d6 (δ 2.50 ppm) for 1H NMR and CDCl3 (δ 77 ppm) for 13C NMR, and 
coupling constants are given in Hz. FAB-MS spectra were measured on a JEOL JMS-700 mass 
spectrometer. Electrospray ionization (ESI) mass spectra were measured on a Bruker MicrOTOF. 
Melting points were determined with a J-Science RFS-10 hot stage microscope. Elemental analysis was 
carried out with a Perkin Elmer 2400 Series II CHNS/O Elemental Analyzer and results were within ± 
0.4% of the theoretical values. The purity of all tested compounds was >95%, as confirmed by HPLC. 
Preparative HPLC. Preparative HPLC was performed using a Shimadzu liquid chromatographic system 
(Kyoto, Japan) consisting of an LC-10AS pump, SPD-10AV UV−vis spectrophotometric detector, 
CTO-10AS column oven and C-R5A Chromatopac. The samples (2 mL) were injected and the 
chromatographic analyses were carried out on an YMC Pack ODS-AM (10 mm i.d. × 250 mm, 5 µm, 
YMC Co., Ltd.) at 40 °C, using MeOH:H2O (85/15 + 0.1% formic acid, v/v) as the mobile phase. The 
flow rate was 0.7 mL/min and the absorbance at 260 nm was monitored. All the solvents were of 
analytical grade and were used directly without purification. 
Analytical HPLC. Analytical HPLC was performed using a Shimadzu liquid chromatographic system 
(Kyoto, Japan) consisting of an LC-10AD pump, SPD-10AV UV−vis spectrophotometric detector, 
CTO-10AS column oven and C-R5A Chromatopac. The samples (each 20 μL) were injected onto an 
Inertsil ODS-3 (4.6 i.d. × 100 mm, 3 μm, GL Sciences, Tokyo, Japan) fitted with a guard column of 
Inertsil ODS-3 (4.0 mm i.d. × 10 mm, 3 μm, GL Sciences) at 40 °C, using MeOH:H2O (85/15 + 0.1% 
formic acid, v/v) as the mobile phase. The flow rate was 0.7 mL/min and the absorbance at 260 nm was 
monitored. 
7-Hydroxy-2-oxo-6-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-2H-chromene-3-
carboxylic acid (10, CU-6PMN). To a solution of 20 (41 mg, 0.12 mmol) and Meldrum's acid (17 mg, 
0.12 mmol) in ethanol (1 mL) was added piperidine (50 µL). The reaction mixture was refluxed for 2 h, 
then poured into water (30 mL), acidified with sat. NH4Cl aq and extracted with EtOAc (2 × 100 mL). 
The organic layer was washed with water (2 × 50 mL) and brine (50 mL), dried over Na2SO4, and 
filtered. The filtrate was evaporated in a rotary evaporator. The residue was recrystallized from 
CH2Cl2/MeOH to yield 27 mg of 10 as a yellow particulate solid (55%). Mp: 229.6−230.1 ºC 1H-NMR 
(300 MHz, DMSO-d6) δ: 8.70 (s, 1H), 7.63 (s, 1H), 7.18 (s, 1H), 7.03 (s, 1H), 6.85 (s, 1H), 2.05 (s, 3H), 
1.65 (s, 4H), 1.27 (s, 6H), 1.22 (s, 6H). 13C-NMR (75 MHz, CDCl3) δ: 165.07, 163.81, 161.22, 156.61, 
151.86, 147.10, 144.34, 134.33, 132.46, 130.14, 129.57, 129.03, 128.88, 112.70, 111.17, 103.66, 51.30, 
45.42, 35.29, 35.26, 34.62, 34.46, 32.30, 32.17, 19.78. FAB-MS m/z: 407 [M + H]+. HRMS (ESI−) m/z: 
[M − H]− Calcd for C25H25O5 405.1707; Found 405.1704. Anal. Calcd for C25H26O5·1/4H2O: C, 73.06; 
H, 6.50. Found: C, 72.69; H, 6.13. Analytical HPLC: 9.8 min; >95% purity. 
7-Hydroxy-2-oxo-8-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)-2H-chromene-3-
carboxylic acid (11). To a solution of 26 (18 mg, 0.053 mmol) and Meldrum's acid (8.0 mg, 0.053 
mmol) in ethanol (1 mL) was added piperidine (50 µL). The reaction mixture was refluxed for 2 h, then 
poured into water (30 mL). The mixture was acidified with 2 M HCl aq and extracted with EtOAc (2 × 
50 mL). The organic layer was washed with water (2 × 50 mL) and brine (50 mL), dried over Na2SO4, 
and filtered. The filtrate was evaporated in a rotary evaporator. The residue was chromatographed (SiO2, 
EtOAc/n-hexane = 1/3, v/v) to yield 20 mg of a yellow solid, which was further purified by preparative 
HPLC (MeOH/H2O = 85/15 + 0.1% formic acid, v/v). The eluate was evaporated under reduced 
pressure to afford 10 mg of 11 as a pale-yellow solid (46%). Mp: 221.7–223.0 ºC 1H-NMR (300 MHz, 
CDCl3) δ: 8.92 (s, 1H), 7.68 (d, 1H, J = 8.8 Hz), 7.32 (s, 1H), 7.16 (d, 1H, J = 8.8 Hz), 7.10 (s, 1H), 
2.06 (s, 3H), 1.72 (s, 4H), 1.37 (s, 3H), 1.33 (s, 3H), 1.26 (s, 6H). 13C-NMR (75 MHz, CDCl3) δ: 164.67, 
163.34, 160.63, 155.83, 151.80, 146.97, 144.00, 134.72, 131.23, 129.55, 128.54, 124.10, 116.64, 114.99, 
112.47, 110.44, 34.92, 34.83, 34.23, 34.05, 32.02, 31.81, 31.76, 31.70, 19.31. FAB-MS m/z: 407 [M + 
H]+. HRMS (ESI−) m/z: [M − H]− Calcd for C25H25O5 405.1707; Found 405.1704. Anal. Calcd for 
C25H26O5·3/2H2O: C, 69.26; H, 6.76. Found: C, 69.65; H, 6.79. Analytical HPLC: 8.8 min; >97% purity. 
6-Bromo-1,1,4,4,7-pentamethyl-1,2,3,4-tetrahydronaphthalene (14). This compound was prepared 
according to references 38 and 39. 2,5-Dimethyl-2,5-hexanediol (12, 2.0 g, 13.6 mmol) was dissolved in 
conc. HCl (20 mL) and the solution was stirred at room temperature for 4 h. The mixture was filtered. 
The filtrate was washed with water and dissolved in CH2Cl2 (150 mL) and the organic solution was 
washed with water (50 mL). The resulting solution was dried over MgSO4, filtered, and evaporated 
using a rotary evaporator to afford 13. Then 13 was dissolved in CH2Cl2 again, and 2-bromotoluene (3.3 
mL, 27 mmol) was added to the solution. Next, AlCl3 (170 mg) was slowly added at 0 ºC under Ar. The 
reaction mixture was stirred at room temperature for 20 h, and then diluted with n-hexane (150 mL). 
The organic layer was collected, washed with water (2 × 50 mL) and brine (50 mL), dried over MgSO4, 
and filtered. The filtrate was evaporated in a rotary evaporator, and the residue was recrystallized from 
methanol to yield 3.0 g of 14 as yellow needles (78%). 1H-NMR (300 MHz, CDCl3) δ: 7.42 (s, 1H), 
7.14 (s, 1H), 2.34 (s, 3H), 1.65 (s, 4H), 1.25 (s, 12H). 13C-NMR (75 MHz, CDCl3) δ: 144.60, 144.06, 
134.57, 130.14, 128.89, 122.12, 34.91, 34.87, 34.00, 33.91, 31.76, 31.72, 22.53. 
(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)boronic acid (15). This compound was 
prepared according to reference 39. A solution of 1.6 M n-BuLi in n-hexane (1.5 mL, 2.4 mmol) was 
slowly added to a solution of 14 (560 mg, 2 mmol) in THF (6 m) at -78 ºC under an Ar atmosphere. The 
reaction mixture was stirred at -78 ºC for 20 min and then a solution of triisopropyl borate (1.4 mL, 6 
mmol) in THF (0.5 mL) was added to it. Stirring was continued at -78 ºC for 2 h. The reaction mixture 
was poured into 2 M HCl aq (10 mL) and the mixture was stirred at room temperature for 1 h and 
diluted with EtOAc (150 mL). The organic layer was collected, washed with water (2 × 50 mL) and 
finally with brine (50 mL). The resulting solution was dried over MgSO4, filtered and evaporated using 
a rotary evaporator. The residue was chromatographed using (SiO2, EtOAc/n-hexane = 1/5, v/v) to yield 
360 mg of 15 as a yellow oil (73%). 1H-NMR (300 MHz, CDCl3) δ: 8.28 (s, 1H), 7.21 (s, 1H), 2.81 (s, 
3H), 1.72 (s, 4H), 1.34 (s, 6H), 1.32 (s, 6H). 13C-NMR (75 MHz, CDCl3) δ: 149.42, 142.89, 141.49, 
136.34, 128.59, 35.06, 35.03, 34.37, 33.82, 31.87, 31.56, 22.70. 
5-Bromo-2,4-dihydroxybenzaldehyde (17). This compound was prepared according to reference 40. 
To a solution of 2,4-dihydroxybenzaldehyde (16, 3.3 g, 24 mmol) in acetic acid (24 mL) was slowly 
added bromine (1.24 mL, 24 mmol). The reaction mixture was stirred at room temperature for 15 h, then 
poured into water (35 mL), and the whole was filtered. The crude product was chromatographed (SiO2, 
EtOAc/n-hexane = 1/4, v/v) and recrystallized from EtOAc/n-hexane to yield 1.46 g of 17 as pale brown 
needles (28%). 1H NMR (300 MHz, CDCl3) δ: 11.25 (s, 1H), 9.70 (d, 1H, J = 1 Hz), 7.66 (s, 1H), 6.63 
(s, 1H), 6.11 (s, 1H). 
5-Bromo-2,4-bis(methoxymethoxy)benzaldehyde (18). DIPEA (520 µL, 3 mmol) and chloromethyl 
methyl ether (324 µL, 4.3 mmol) were added to a solution of 17 (220 mg, 1 mmol) in DMF (3 m) at 0 
ºC under an Ar atmosphere. The reaction mixture was stirred at room temperature for 27 h, then poured 
into sat. NH4Cl aq (60 mL) and extracted with EtOAc (3 × 40 mL). The organic layer was collected, 
washed with water (2 × 60 mL) and brine (60 mL), dried over MgSO4, and filtered. The filtrate was 
evaporated in a rotary evaporator. The residue was chromatographed (SiO2, EtOAc/n-hexane = 1/5, v/v) 
to yield 280 mg of 18 as a white solid (92%). 1H-NMR (300 MHz, CDCl3) δ: 10.29 (s, 1H), 8.03 (s, 1H), 
7.01 (s, 1H), 5.32 (s, 2H), 5.29 (s, 2H), 3.53 (s, 6H). 13C-NMR (75 MHz, CDCl3) δ: 187.01, 160.24, 
159.10, 132.36, 120.61, 105.39, 101.92, 94.75, 56.59, 56.52. 
2,4-Bis(methoxymethoxy)-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-
yl)benzaldehyde (19). To a solution of 15 (200 mg, 0.8 mmol) and 18 (150 mg, 0.49 mmol) in toluene 
(2 mL) and ethanol (1 mL) were added tetrakis(triphenylphosphine)palladium (30 mg, 0.026 mmol) and 
2 M Na2CO3 aq (0.5 mL). The reaction mixture was stirred at 100 ºC for 24 h, then diluted with EtOAc 
(150 mL). The organic layer was collected, washed with sat. NH4Cl aq (100 mL), water (100 mL) and 
brine (100 mL), dried over MgSO4, and filtered. The filtrate was evaporated in a rotary evaporator. The 
residue was chromatographed (SiO2, EtOAc/n-hexane = 1/6, v/v) to yield 180 mg of 19 as a colorless oil 
(86%). 1H-NMR (300 MHz, CDCl3) δ: 10.39 (s, 1H), 7.69 (s, 1H), 7.13 (s, 1H), 7.04 (s, 2H), 5.34 (s, 
2H), 5.16 (s, 2H), 3.57 (s, 3H), 3.39 (s, 3H), 2.10 (s, 3H), 1.69 (s, 4H), 1.31 (s, 6H), 1.25 (s, 6H). 13C-
NMR (75 MHz, CDCl3) δ: 188.31, 160.69, 160.47, 143.81, 141.76, 134.10, 133.38, 131.20, 128.19, 
127.41, 126.24, 119.63, 101.02, 94.80, 94.52, 56.55, 56.36, 35.09, 33.87, 33.79, 31.84, 31.81, 31.49, 
22.56, 19.66, 14.10. 
2,4-Dihydroxy-5-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzaldehyde (20). To 
a solution of 19 (171 mg, 0.4 mmol) in EtOAc (2 mL) was added 4 M HCl/EtOAc (2 mL). The reaction 
mixture was stirred at room temperature for 4 h and evaporated in a rotary evaporator. The residue was 
chromatographed (SiO2, EtOAc/n-hexane = 1/5, v/v) to yield 117 mg of 20 as a yellow solid (88%). 1H-
NMR (300 MHz, CDCl3) δ: 11.37 (1H, s), 9.72 (1H, s), 7.32 (1H, s), 7.25 (1H, s), 7.12 (1H, s), 6.56 (1H, 
s), 5.52 (1H, s), 2.11 (4H, s), 1.71 (4H, s), 1.32 (6H, s), 1.27 (6H, s). 13C-NMR (75 MHz, CDCl3) δ: 
194.45, 163.51, 160.93, 145.77, 143.47, 135.99, 134.27, 130.69, 128.80, 128.77, 121.74, 115.19, 102.82, 
60.53, 34.91, 34.05, 33.94, 31.84, 31.72, 21.02, 19.38, 14.10. 
1,3-Bis(methoxymethoxy)benzene (22). This compound was prepared according to reference 41. To a 
suspension of 60% NaH (920 mg, 23 mmol) in DMF (10 mL) was added a solution of resorcinol (21, 
1.1 g, 10 mmol) in DMF (10 mL). The mixture was stirred at 0 ºC under an Ar atmosphere for 15 min, 
then chloromethyl methyl ether (1.67 mL, 22 mmol) was added, and stirring was continued at room 
temperature for 27 h. The reaction mixture was poured into ice-cold water (50 mL) and extracted with 
EtOAc (2 × 100 mL). The organic layer was collected, washed with water (2 × 50 mL) and brine (50 
mL), dried over MgSO4, and filtered. The filtrate was evaporated in a rotary evaporator to yield 1.98 g 
of 22 as a clear oil (q.y.). 1H-NMR (400 MHz, CDCl3) δ: 7.19 (t, 1H, J = 8.2 Hz), 6.74 (d, 1H, J = 2.2 
Hz), 6.70 (dd, 2H, J = 8.2, 2.2 Hz), 5.16 (s, 4H), 3.48 (s, 6H). 13C-NMR (75MHz, CDCl3) δ: 158.17, 
129.70, 109.31, 104.67, 94.12, 55.66. 
(2,6-Bis(methoxymethoxy)phenyl)boronic acid (23). This compound was prepared according to 
reference 41. To a solution of 22 (297 mg, 1.5 mmol) in Et2O (6 mL) was slowly added 1.6 M n-BuLi in 
n-hexane solution (1.13 mL, 1.8 mmol) at 0 ºC under an Ar atmosphere. The reaction mixture was 
stirred at room temperature for 3 h, then trimethyl borate (250 µL, 2.25 mmol) was added, and stirring 
was continued at room temperature for 1 h. The reaction mixture was poured into 2 M HCl aq (10 mL). 
The whole was stirred at room temperature for 1 h. The mixture was filtered, washed with water, and 
dried under reduced pressure to yield 177 mg of 23 as a pale-yellow solid (49%). 1H-NMR (300 MHz, 
CDCl3) δ: 7.36 (t, 1H, J = 8.3 Hz), 7.23 (s, 2H), 6.88 (d, 2H, J = 8.3 Hz), 5.30 (s, 4H), 3.51 (s, 6H). 13C-
NMR (75 MHz, CDCl3) δ: 163.02, 133.00, 108.23, 94.78, 56.58. 
6-(2,6-Bis(methoxymethoxy)phenyl)-1,1,4,4,7-pentamethyl-1,2,3,4-tetrahydronaphthalene (24). To 
a solution of 13 (113 mg, 0.4 mmol) and 23 (145 mg, 0.6 mmol) in DME (4 mL) were added 
tetrakis(triphenylphosphine)palladium (69 mg, 0.06 mmol), K3PO4 (255 mg, 1.2 mmol) and H2O (1.3 
mL). The reaction mixture was refluxed for 30 min, then poured into water (30 mL) and extracted with 
EtOAc (3 × 30 mL). The organic layer was collected, washed with water (2 × 50 mL) and brine (50 mL), 
dried over MgSO4, and filtered. The filtrate was evaporated in a rotary evaporator. The residue was 
chromatographed (SiO2, EtOAc/n-hexane = 1/30, v/v) to yield 124 mg of 24 as a white solid (78%). 1H-
NMR (400 MHz, CDCl3) δ: 7.24 (t, 1H, J = 8.4 Hz), 7.13 (s, 1H), 7.05 (s, 1H), 6.89 (d, 2H, J = 8.4 Hz), 
5.04 (d, 2H, J = 6.6 Hz), 4.96 (d, 2H, J = 6.6 Hz), 3.27 (s, 6H), 2.07 (s, 3H), 1.68 (s, 4H), 1.55 (s, 3H), 
1.30 (s, 6H), 1.23 (s, 6H). 13C-NMR (75 MHz, CDCl3) δ: 155.50, 143.21, 141.10, 133.93, 131.01, 
129.93, 128.86, 128.34, 127.09, 122.91, 109.69, 109.59, 94.93, 94.43, 55.88, 35.33, 35.26, 34.92, 34.89, 
33.93, 33.82, 31.93, 31.90, 31.76, 19.55. 
2-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzene-1,3-diol (25). To a solution of 
24 (108 mg, 0.27 mmol) was added 4 M HCl/EtOAc (2 mL). The reaction mixture was stirred at room 
temperature for 3 h, then poured into water (30 mL) and extracted with EtOAc (30 mL). The organic 
layer was collected, washed with water (30 mL) and brine (30 mL), dried over MgSO4, and filtered. The 
filtrate was evaporated in a rotary evaporator. The residue was chromatographed using (SiO2, EtOAc/n-
hexane = 1/8, v/v) to yield 45 mg of 25 as a pale-yellow solid (54%). 1H-NMR (300 MHz, CDCl3) δ: 
7.31 (s, 1H), 7.18 (s, 1H), 7.15 (d, 1H, J = 8.0 Hz), 6.59 (d, 2H, J = 8.0 Hz), 4.72 (s, 2H), 2.10 (s, 3H), 
1.71 (s, 4H), 1.33 (s, 6H), 1.25 (s, 6H). 13C-NMR (75 MHz, CDCl3) δ: 153.48, 146.69, 144.66, 144.42, 
135.90, 130.16, 129.63, 129.53, 129.35, 128.91, 125.92, 114.76, 107.13, 34.95, 34.89, 34.19, 34.07, 
31.88, 31.75, 31.70, 19.05. 
2,4-Dihydroxy-3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzaldehyde (26). 
POCl3 (100 µL) was added to DMF (350 µL) at 0 ºC. The reaction mixture was stirred for 1.5 h, and 
then a solution of 25 (40 mg, 0.128 mmol) in DMF (1.5 mL) was added to it, and stirring was continued 
at room temperature for 48 h. The reaction mixture was poured into ice-cold water (30 mL), adjusted to 
pH 3 with sat. NaHCO3 aq., and extracted with EtOAc (2 × 50 mL). The organic layer was washed with 
water (2 × 50 mL) and brine (50 mL), dried over MgSO4, and filtered. The filtrate was evaporated in a 
rotary evaporator. The residue was chromatographed (SiO2, EtOAc/n-hexane = 1/8, v/v) to yield 17 mg 
of 26 as a pale-yellow solid (39%). 1H-NMR (300 MHz, CDCl3) δ: 11.71 (s, 1H), 9.76 (s, 1H), 7.48 (d, 
1H, J = 8.4 Hz), 7.28 (s, 1H), 7.11 (1H, s), 6.69 (1H, d, J = 8.4 Hz), 5.69 (s, 1H), 2.10 (s, 3H), 1.70 (s, 
4H), 1.33 (s, 3H), 1.31 (s, 3H), 1.26 (s, 6H). 13C-NMR (75 MHz, CDCl3) δ: 194.69, 161.13, 160.63, 
146.03, 143.59, 135.27, 134.89, 129.18, 128.68, 125.87, 115.72, 115.10, 108.20, 35.01, 34.95, 34.14, 
32.07, 31.85, 31.73, 31.69, 19.20, 14.18. 
In vitro assays 
Reporter gene assay. Luciferase reporter gene assays using COS-1 cells were performed according to 
reference 42. Briefly, COS-1 cells were transfected with three kinds of vectors consisting of human 
RXR receptor alpha, a luciferase reporter gene under the control of the appropriate RXR response 
element (CRBPII-tk-Luc), and secreted alkaline phosphatase (SEAP) gene as a background. Test 
compound solutions (DMSO concentration: 1%) were added to a suspension of transfected cells seeded 
at about 2.0×104 cells/well in 96-well white plates. After incubation in a humidified atmosphere of 5% 
CO2 at 37ºC for 24 h, 25 µL of the medium was used for analysis of SEAP activity, and the remaining 
cells were used for luciferase reporter gene assays with a Steady-Glo Luciferase Assay system 
(Promega) according to the supplier’s protocol. The luciferase activities were normalized using the 
SEAP activities. The assays were carried out three times in triplicate. 
Ligand binding assay using radioligand. Competitive binding assay using 9-cis-[11,12-3H]-retinoic 
acid ([3H]1) was performed as described in references 43 and 44 with some modifications. [3H]1, 
NET1151, 1.11–2.22 TBq/mmol (30–60 Ci/mmol) 7.4 MBq/mL (0.2 mCi/mL)) was purchased from 
PerkinElmer (USA). hRXRα-LBD (NR2B1, Catalog No: 31135) was purchased from Active Motif, Inc 
(USA). Dextran-coated charcoal (DCC) was purchased from Sigma-Aldrich. Assay buffer contained 20 
mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 5 mM dithiothreitol (DTT), 10% glycerol. 
hRXRα-LBD, 3, and [3H]1 were diluted as required with the assay buffer described above. 
Kd determination of [3H]1. To a 1.5 mL Eppendorf tube were added 30 µL of serial dilutions of 
hRXRα-LBD (3,000 nM to 3 nM, common ratio 3, 12 final concentration levels), 15 µL of 2% DMSO 
assay buffer or 40 µM bexarotene (final concentration 10 µM), and 15 µL of 40 nM [3H]1 (final 
concentration was 10 nM). Three samples per test condition were used. The mixture was incubated at 
4°C overnight. [3H]1 bound to hRXRα-LBD was separated from free [3H]1 by adding 20 µL of ice-cold 
0.4% DCC suspension to each sample. The samples were placed on ice for 1 min and the reaction 
mixture was centrifuged at 12,000 rpm (8,000×g) at 4°C for 5 min. Fifty microliters of each supernatant 
was poured into a scintillation vial containing 3 mL scintillation cocktail and bound radioactivity was 
determined by liquid scintillation counting of the solution. The specific equilibrium binding constant 
(Kd) was derived from the specific binding curve by fitting the data into a sigmoid equation using Excel 
software. The Kd value of [3H]1 was obtained as 37 nM. The concentration of hRXRα-LBD was 50 nM. 
IC50 determination of test compounds using [3H]1. To a 1.5 mL Eppendorf tube were added 30 µL of 
100 nM hRXRα-LBD, 15 µL of serial dilutions of test compounds (10,000 nM to 1 nM, common ratio 3, 
9 final concentration levels) in assay buffer containing 8% DMSO, and 15 µL of 40 nM [3H]1 (final 
concentration 10 nM). Three samples per test condition were used. The mixture was incubated at 4°C 
overnight, and bound radioligand was separated from free as described above. IC50 was derived from the 
binding curve by fitting the data to a sigmoid equation using Excel software. The inhibition constant 
(Ki) value was calculated as described below. 
Ki calculation from IC50. The inhibition constant (Ki) value of each test compound was calculated by 
using equation 1.31 
Ki = IC50/(1 + [L]/Kd) -------- (1) 
where IC50 is the concentration of test compound that inhibits 50% of binding, [L] is the concentration 
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Crystallization and X-ray data collection of hRXRα-LBD/10, UV–vis and fluorescence spectra 
measurements, fluorescence quantum yield determination, Kd determination of CU-6PMN (10), 
transformation of measured fluorescence intensity into bound receptor concentration, binding affinity 
assay of a panel of RXR ligands with hRXRα-LBD using CU-6PMN (10), Z’-factor, statistical analysis, 
chemical structures of the compounds used, absorbance and fluorescent spectra, binding assay protocol, 
NMR spectra, HPLC charts (PDF). 
Molecular formula strings and some data (CSV). 
Atomic coordinates of hRXRα-LBD/10 (PDB ID: 6JNO) by binding mode analysis (PDB). The 
atomic coordinates will be released when the article is published. 
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Abs, absorption; ACN, acetonitrile; DHA, docosahexaenoic acid; DTT, dithiothreitol; EPA, 
eicosapentaenoic acid; Em, emission; Ex, excitation; Fl, fluorescence; HPLC, high performance liquid 
chromatography; hRXR, human RXR; LBD, ligand-binding domain; LBP, ligand-binding pocket; LXR, 
liver X receptor; MS, mass spectrometry; Nurr1, nuclear receptor related 1 protein; PPAR, peroxisome 
proliferator activated receptor; RAR, retinoic acid receptor; RI, radioisotope; RXR, retinoid X receptor; 
SD, standard deviation; TR-FRET, time-resolved fluorescence resonance energy transfer. 
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